Bleeding and Ischemic Risks of Ticagrelor Monotherapy After Coronary Interventions.
Guiomar MendietaShamir MehtaUsman BaberDominick J AngiolilloCarlo BriguoriDavid CohenTimothy CollierGeorge DangasDariusz DudekJavier EscanedRobert GilBirgit VogelDavide CaoAlessandro SpiritoKurt HuberAdnan KastratiUpendra KaulRan KornowskiMitchell W KrucoffVijay KunadianDavid J MoliternoE Magnus OhmanGennaro SardellaSamantha SartoriSamin SharmaRichard ShlofmitzP Gabriel StegYa-Ling HanStuart PocockC Michael GibsonRoxana MehranPublished in: Journal of the American College of Cardiology (2023)
Three months after PCI, discontinuing aspirin and maintaining ticagrelor monotherapy reduces bleeding in both higher-bleeding risk and lower-bleeding risk patients compared with continued DAPT. This benefit does not appear to be offset by greater ischemic risk. (Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention [TWILIGHT]; NCT02270242).
Keyphrases
- antiplatelet therapy
- percutaneous coronary intervention
- acute coronary syndrome
- end stage renal disease
- coronary artery disease
- atrial fibrillation
- ejection fraction
- low dose
- chronic kidney disease
- newly diagnosed
- st segment elevation myocardial infarction
- st elevation myocardial infarction
- randomized controlled trial
- coronary artery
- acute myocardial infarction
- cardiovascular disease
- heart failure
- prognostic factors
- type diabetes
- peritoneal dialysis
- left ventricular
- cardiovascular events
- risk assessment
- aortic stenosis
- ischemia reperfusion injury
- clinical trial
- blood brain barrier
- human health
- patient reported
- aortic valve